Pruritus occurs in up to 70% of patients with primary biliary cholangitis (PBC), can be severe, and lead to increased morbidity-including worsening fatigue and quality of sleep. Standard of care treatment has relied on a variety of medications with limited effectiveness and tolerability adding to the patient disease burden. In this 1-hour video-based activity with animation, Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.
Course Credit:
1 AAPA Category I Hour
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
Dates:
Opens: 2024-12-27
Closes: 2025-12-27
Target Audience:
This activity was developed for gastroenterologists, hepatologists, nurse practitioners, physician associates, and pharmacists who have a role in the management and monitoring of patients with primary biliary cholangitis.
This activity is supported by an educational grant from GlaxoSmithKline.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Eugene Cullen, MD (Peer Reviewer)No significant relationships to disclose.
Tim Drake, PharmD, MBA, BCPS (Medical Writer)
No significant relationships to disclose.
Donald Gardenier, DNP (Nurse Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Alan Bonder, MD
Medical Director of Liver Transplant
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts -
Kris Kowdley, MD
Director, Liver Institute Northwest
Medical Director and Senior Scientific Advisor, Velocity Clinical Research
Professor, Elson S. Floyd College of Medicine
Washington State University
Seattle, Washington
Presenting Faculty
Downloads
Learning Objectives
- Regularly assess the burden of disease and reduced quality of life experienced by patients with cholestatic pruritus
- Individualize treatment in collaboration with the patient consistent with guideline recommendations and evolving evidence
- Gain understanding of the safety and efficacy of pharmacologic options in late-phase investigation
Faculty Disclosures
Alan Bonder, MD
Consultant: Alfasigma, Alnylam, Chemomab, CymaBay, GSK, Guidepoint; Intercept, Ipsen
Medical Reviewer: Pfizer
Research Support: Alfasigma, Alnylam, Chemomab, CymaBay, GSK, Intercept, Ipsen, Mirum
Kris Kowdley, MD
Advisory Board: Medpace, MSD
Consultant: 89bio, Arbormed, Boehringer Ingelheim CymaBay, Genfit, Gilead, GSK, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Novo Nordisk, Orphalan, Pfizer, Zydus
Speakers Bureau: AbbVie, Gilead, Intercept, Ipsen
Stock: Inipharm